Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Severe acute respiratory virus syndrome 2 (SARS-CoV-2) has led to a worldwide pandemic.
Early studies in solid organ transplant (SOT) recipients suggested a wide variety of …

To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose …

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) exploded onto the world stage in early …

In the absence of effective countermeasures, human convalescent plasma has been widely
used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel …

Introduction The coronavirus disease 2019 (COVID-19) pandemic has spread globally.
Therapeutic options including antivirals, anti-inflammatory compounds, and vaccines are still …

Major changes have occurred in therapeutics for coronavirus-19 (COVID-19) infection over
the past 12–18 mo, most notably in early outpatient therapy. In most cases, solid organ …

Immunosuppressed patients such as solid organ transplant and hematologic malignancy
patients appear to be at increased risk for morbidity and mortality due to coronavirus disease …

ABSTRACT Introduction: The ongoing SARS-CoV-2 pandemic is a serious threat for the
health of immunocompromised patients. Among neutralizing antibody-based therapeutics …

Background: The COVID-19 pandemic, caused by a novel coronavirus termed SARS-CoV-2,
has spread quickly worldwide. Convalescent plasma (CP) obtained from patients following …